A Phase 2, Randomized, Controlled, Observer-Blinded Study to Describe the Immunogenicity, Safety, and Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Trial Profile

A Phase 2, Randomized, Controlled, Observer-Blinded Study to Describe the Immunogenicity, Safety, and Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs PF 5212366 (Primary) ; Hepatitis A vaccine inactivated
  • Indications Meningococcal group B infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 06 Apr 2017 This trial has been completed in Finland (End date:2017-03-01) as per European Clinical Trials Database record.
    • 05 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2017 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top